Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomes

Breast cancer is the leading cause of cancer-associated death for women worldwide. While chemotherapy is the mainstream treatment for breast cancer, more than 50% of women undergoing chemotherapy will experience at least one chemotherapy-related adverse side effect. Sometimes, the side effects could be so severe that patients need to terminate treatment early or doctors have to reduce the chemo dosage, and this could worsen their disease. Prolonged exposure to high doses of chemotherapeutic agents could also result in resistance to chemotherapy.

A team of researchers from the National University of Singapore (NUS) is pioneering a novel magnetic therapy — delivered using the OncoFTX System — that serves as an effective companion therapy to chemotherapy to enhance treatment outcome for breast cancer.

Our magnetic technology stimulates cellular oxygen respiration to produce energy. In certain cancers with elevated respiratory rates — such as breast tumors — the magnetic pulses cause the cancer cells to ‘hyperventilate’ and die. Fortunately, the healthy tissues near the cancer are able to tolerate the increased respiratory rate, without ill consequences. Therefore, the OncoFTX System is more selective for cancer than conventional chemotherapy or radiotherapy. Importantly, this therapy is localized, non-invasive and painless.

Quantum cyber threats are likely years away. Why — and how — we’re working today to stop them

This was Mastercard in March: You probably do it every day without a second thought — shop online with your credit card, or install an update on your phone, or send a confidential file to a co-worker.


Mastercard’s efforts include a pilot to test whether quantum key distribution would work on its complex global network.

New medical procedure for treating irregular heart rhythm

The technology is designed to treat the condition atrial fibrillation, or irregular heart rhythm. This is in a way that carries a lower risk of complications and shorter anaesthesia time (when compared to traditional treatment).

The new technology took eighteen years to develop. In recent months, pulsed field ablation has been approved by the U.S. Food and Drug Administration (FDA) and the acceptance marks a milestone in heart treatment.

The process involves the use of microsecond-scale, high-voltage electrical fields to cause irreversible electroporation and destabilization of cell membranes, according to the New England Journal of Medicine.